Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Siddharth M PatelYu Mi KangKyungAh ImBrendon L NeuenStefan D AnkerDeepak L BhattJaved ButlerDavid Z I CherneyBrian Lee ClaggettRobert A FletcherWilliam G HerringtonCatherine M ViscoliMeg J JardineKenneth W MahaffeyDarren K McGuireJohn Joseph Valentine McMurrayBruce C NealMilton PackerVlado PerkovicScott D SolomonNatalie StaplinMuthiah VaduganathanChristoph WannerDavid Collins WheelerFaiez ZannadYujie ZhaoHiddo J Lambers HeerspinkMarc S SabatineStephen D WiviottPublished in: Circulation (2024)
SGLT2i reduce the risk of MACE across a broad range of patients irrespective of ASCVD, diabetes, kidney function or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of CV death, particularly HF and sudden cardiac death, without a significant effect on MI in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.